Biology Reference
In-Depth Information
[95] Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, et al. Tumor necrosis
factor-alpha blockade for the treatment of acute GVHD. Blood 2004;104(3):649-54.
[96] Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, et al. Etanercept
plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood
2008;111(4):2470-5.
[97] Holler E, Kolb HJ, Mittermuller J, Kaul M, Ledderose G, Duell T, et al. Modulation of
acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor
necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning:
role of conditioning regimens and prophylactic application of a monoclonal antibody
neutralizing human TNF alpha (MAK 195F). Blood 1995;86(3):890-99.
[98] Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter S, Difronzo N, et al. Etaner-
cept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute graft vs.
host disease: a randomized phase II trial from the BMT CTN. Blood 2009;114(3):511-17.
[99] Baron C, Somogyi R, Greller LD, Rineau V, Wilkinson P, Cho CR, et al. Prediction of
graft-versus-host disease in humans by donor gene-expression profiling. PLoS Med
2007;4(1):e23.
[100] Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, et al. A biomark-
er panel for acute graft-versus-host disease. Blood 2009;113(2):273-8.
[101] Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-
leukemia reactions after bone marrow transplantation. Blood 1990;75(3):555-62.
[102] Vincent K, Roy DC, Perreault C. Next-generation leukemia immunotherapy. Blood
2012;118(11):2951-9.
[103] Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes.
Blood 2008;112(12):4371-83.
[104] Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: indi-
vidualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010;10(3):213-21.
17
Search WWH ::
Custom Search